F-18 FDG PET for evaluation of bone marrow involvement in non-hodgkin lymphoma: A meta-analysis

Yen Kung Chen, Chia Lu Yeh, Chih Cheng Tsui, Ji An Liang, Jin Hua Chen, Chia Hung Kao

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: In recent years, the use of F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has become widespread for the staging of lymphoma. In non-Hodgkin lymphoma (NHL), the bone marrow (BM) involvement is a sign of extensive disease, and the iliac crest BM biopsy (BMB) is the established method for the detection of BM infiltration. However, iliac crest BMB is associated with a high rate of false-negative results. We assess the ability of FDG PET or PET/CT scan to ascertain the presence of BM involvement in aggressive and indolent NHL. Methods: The authors conducted a systematic MEDLINE search of articles published (last update, May 2010). Two reviewers independently assessed the methodological quality of each study. A meta-analysis of the reported sensitivity and specificity of each study was performed. Results: Eight studies met the inclusion criteria. The studies had several design deficiencies. Pooled sensitivity and specificity for the detection of non-Hodgkin aggressive lymphoma were 0.74 (95% CI, 0.65-0.83) and 0.84 (95% CI, 0.80-0.89), respectively. Pooled sensitivity and specificity for the detection of non-Hodgkin indolent lymphoma were 0.46 (95% CI, 0.33-0.59) and 0.93 (95% CI, 0.88-0.98), respectively. Conclusions: The diagnostic accuracy of FDG PET or PET/CT scans was slightly higher but without significant statistical difference (P = 0.1507) in patients with non-Hodgkin aggressive lymphoma as compared with those with non-Hodgkin indolent lymphoma. The sensitivity to detect indolent lymphoma BM infiltration was low for FDG PET or PET/CT.

Original languageEnglish
Pages (from-to)553-559
Number of pages7
JournalClinical Nuclear Medicine
Volume36
Issue number7
DOIs
Publication statusPublished - Jul 2011
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Non-Hodgkin's Lymphoma
Meta-Analysis
Bone Marrow
Sensitivity and Specificity
Lymphoma
Biopsy
MEDLINE
Positron Emission Tomography Computed Tomography

Keywords

  • aggressive non-Hodgkin lymphoma
  • bone marrow involvement
  • FDG
  • indolent lymphoma
  • PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

F-18 FDG PET for evaluation of bone marrow involvement in non-hodgkin lymphoma : A meta-analysis. / Chen, Yen Kung; Yeh, Chia Lu; Tsui, Chih Cheng; Liang, Ji An; Chen, Jin Hua; Kao, Chia Hung.

In: Clinical Nuclear Medicine, Vol. 36, No. 7, 07.2011, p. 553-559.

Research output: Contribution to journalArticle

Chen, Yen Kung ; Yeh, Chia Lu ; Tsui, Chih Cheng ; Liang, Ji An ; Chen, Jin Hua ; Kao, Chia Hung. / F-18 FDG PET for evaluation of bone marrow involvement in non-hodgkin lymphoma : A meta-analysis. In: Clinical Nuclear Medicine. 2011 ; Vol. 36, No. 7. pp. 553-559.
@article{4c6159e339b44b27872256bb4b6e1a28,
title = "F-18 FDG PET for evaluation of bone marrow involvement in non-hodgkin lymphoma: A meta-analysis",
abstract = "Background: In recent years, the use of F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has become widespread for the staging of lymphoma. In non-Hodgkin lymphoma (NHL), the bone marrow (BM) involvement is a sign of extensive disease, and the iliac crest BM biopsy (BMB) is the established method for the detection of BM infiltration. However, iliac crest BMB is associated with a high rate of false-negative results. We assess the ability of FDG PET or PET/CT scan to ascertain the presence of BM involvement in aggressive and indolent NHL. Methods: The authors conducted a systematic MEDLINE search of articles published (last update, May 2010). Two reviewers independently assessed the methodological quality of each study. A meta-analysis of the reported sensitivity and specificity of each study was performed. Results: Eight studies met the inclusion criteria. The studies had several design deficiencies. Pooled sensitivity and specificity for the detection of non-Hodgkin aggressive lymphoma were 0.74 (95{\%} CI, 0.65-0.83) and 0.84 (95{\%} CI, 0.80-0.89), respectively. Pooled sensitivity and specificity for the detection of non-Hodgkin indolent lymphoma were 0.46 (95{\%} CI, 0.33-0.59) and 0.93 (95{\%} CI, 0.88-0.98), respectively. Conclusions: The diagnostic accuracy of FDG PET or PET/CT scans was slightly higher but without significant statistical difference (P = 0.1507) in patients with non-Hodgkin aggressive lymphoma as compared with those with non-Hodgkin indolent lymphoma. The sensitivity to detect indolent lymphoma BM infiltration was low for FDG PET or PET/CT.",
keywords = "aggressive non-Hodgkin lymphoma, bone marrow involvement, FDG, indolent lymphoma, PET/CT",
author = "Chen, {Yen Kung} and Yeh, {Chia Lu} and Tsui, {Chih Cheng} and Liang, {Ji An} and Chen, {Jin Hua} and Kao, {Chia Hung}",
year = "2011",
month = "7",
doi = "10.1097/RLU.0b013e318217aeff",
language = "English",
volume = "36",
pages = "553--559",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - F-18 FDG PET for evaluation of bone marrow involvement in non-hodgkin lymphoma

T2 - A meta-analysis

AU - Chen, Yen Kung

AU - Yeh, Chia Lu

AU - Tsui, Chih Cheng

AU - Liang, Ji An

AU - Chen, Jin Hua

AU - Kao, Chia Hung

PY - 2011/7

Y1 - 2011/7

N2 - Background: In recent years, the use of F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has become widespread for the staging of lymphoma. In non-Hodgkin lymphoma (NHL), the bone marrow (BM) involvement is a sign of extensive disease, and the iliac crest BM biopsy (BMB) is the established method for the detection of BM infiltration. However, iliac crest BMB is associated with a high rate of false-negative results. We assess the ability of FDG PET or PET/CT scan to ascertain the presence of BM involvement in aggressive and indolent NHL. Methods: The authors conducted a systematic MEDLINE search of articles published (last update, May 2010). Two reviewers independently assessed the methodological quality of each study. A meta-analysis of the reported sensitivity and specificity of each study was performed. Results: Eight studies met the inclusion criteria. The studies had several design deficiencies. Pooled sensitivity and specificity for the detection of non-Hodgkin aggressive lymphoma were 0.74 (95% CI, 0.65-0.83) and 0.84 (95% CI, 0.80-0.89), respectively. Pooled sensitivity and specificity for the detection of non-Hodgkin indolent lymphoma were 0.46 (95% CI, 0.33-0.59) and 0.93 (95% CI, 0.88-0.98), respectively. Conclusions: The diagnostic accuracy of FDG PET or PET/CT scans was slightly higher but without significant statistical difference (P = 0.1507) in patients with non-Hodgkin aggressive lymphoma as compared with those with non-Hodgkin indolent lymphoma. The sensitivity to detect indolent lymphoma BM infiltration was low for FDG PET or PET/CT.

AB - Background: In recent years, the use of F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has become widespread for the staging of lymphoma. In non-Hodgkin lymphoma (NHL), the bone marrow (BM) involvement is a sign of extensive disease, and the iliac crest BM biopsy (BMB) is the established method for the detection of BM infiltration. However, iliac crest BMB is associated with a high rate of false-negative results. We assess the ability of FDG PET or PET/CT scan to ascertain the presence of BM involvement in aggressive and indolent NHL. Methods: The authors conducted a systematic MEDLINE search of articles published (last update, May 2010). Two reviewers independently assessed the methodological quality of each study. A meta-analysis of the reported sensitivity and specificity of each study was performed. Results: Eight studies met the inclusion criteria. The studies had several design deficiencies. Pooled sensitivity and specificity for the detection of non-Hodgkin aggressive lymphoma were 0.74 (95% CI, 0.65-0.83) and 0.84 (95% CI, 0.80-0.89), respectively. Pooled sensitivity and specificity for the detection of non-Hodgkin indolent lymphoma were 0.46 (95% CI, 0.33-0.59) and 0.93 (95% CI, 0.88-0.98), respectively. Conclusions: The diagnostic accuracy of FDG PET or PET/CT scans was slightly higher but without significant statistical difference (P = 0.1507) in patients with non-Hodgkin aggressive lymphoma as compared with those with non-Hodgkin indolent lymphoma. The sensitivity to detect indolent lymphoma BM infiltration was low for FDG PET or PET/CT.

KW - aggressive non-Hodgkin lymphoma

KW - bone marrow involvement

KW - FDG

KW - indolent lymphoma

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=79958277379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958277379&partnerID=8YFLogxK

U2 - 10.1097/RLU.0b013e318217aeff

DO - 10.1097/RLU.0b013e318217aeff

M3 - Article

C2 - 21637057

AN - SCOPUS:79958277379

VL - 36

SP - 553

EP - 559

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 7

ER -